Back to Search
Start Over
Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients
- Source :
- AIDS, AIDS, Lippincott, Williams & Wilkins, 2017, 31 (17), pp.2355-2365. ⟨10.1097/QAD.0000000000001628⟩
- Publication Year :
- 2017
- Publisher :
- HAL CCSD, 2017.
-
Abstract
- To evaluate the predictive value of soluble suppression of tumorigenicity 2 (sST2), a decoy receptor of IL-33 involved in several inflammatory and immune diseases, for death in HIV infection.Patients enrolled in the ANRS CO3 Aquitaine Cohort, a prospective hospital-based cohort of HIV-1-infected patients, who had a plasma sample available in the biobank were systematically eligible.sST2, soluble CD14 (sCD14) and IL-6 were measured using Luminex multiplex bead-based technology (RD Systems) and a Bio-Plex 200 instrument (BioRad). Predictive capacities of sST2, sCD14, IL-6 and of the Veterans Aging Cohort Study clinical score at baseline on overall mortality were compared using multivariable Cox proportional hazards models.During a median follow-up of 7.2 years [interquartile range (IQR): 6.0; 7.9], 93 deaths from all causes (incidence rate 9.9 per 1000 patient-years; 95% confidence interval 7.9-11.9) were reported in 1414 patients. The median sST2 baseline concentration was 22.9 ng/ml (IQR: 17.7; 30.3) and was higher (30.8 ng/ml, IQR: 21.5; 42.1) in patients who died as compared with those who stayed alive (22.6 ng/ml; IQR: 17.5; 29.6) (P 10). An increased risk of death of 21% for a concentration 10.0 ng/ml higher of sST2 remained after adjustment for sCD14, IL-6 and Veterans Aging Cohort Study score (adjusted hazard ratio: 1.21; P 10). The predictive capacity of sST2 was confirmed in a validation cohort (n = 386, 31 deaths) with an improved area c-index from 0.804 without sST2 to 0.811 with sST2.sST2 is a new valuable biomarker to evaluate the risk of all-cause mortality in HIV disease.
- Subjects :
- 0301 basic medicine
Adult
Male
Serum
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
Immunology
Lipopolysaccharide Receptors
HIV Infections
Risk Assessment
03 medical and health sciences
0302 clinical medicine
Internal medicine
Immunology and Allergy
Medicine
Humans
030212 general & internal medicine
Prospective Studies
Prospective cohort study
Survival analysis
ComputingMilieux_MISCELLANEOUS
business.industry
Interleukin-6
Hazard ratio
Middle Aged
Prognosis
Interleukin-1 Receptor-Like 1 Protein
Survival Analysis
Confidence interval
3. Good health
030104 developmental biology
Infectious Diseases
Cohort
Biomarker (medicine)
Female
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
Risk assessment
Biomarkers
Cohort study
Subjects
Details
- Language :
- English
- ISSN :
- 02699370
- Database :
- OpenAIRE
- Journal :
- AIDS, AIDS, Lippincott, Williams & Wilkins, 2017, 31 (17), pp.2355-2365. ⟨10.1097/QAD.0000000000001628⟩
- Accession number :
- edsair.doi.dedup.....281092e6179fb6f780b64e7c375a67e9